Quarterly report pursuant to Section 13 or 15(d)

Strategic Alliances (Details)

v3.7.0.1
Strategic Alliances (Details) - USD ($)
1 Months Ended 3 Months Ended 11 Months Ended 76 Months Ended
May 31, 2016
Jan. 31, 2015
Dec. 31, 2010
Mar. 31, 2017
Mar. 31, 2016
Mar. 31, 2017
Mar. 31, 2017
Dec. 31, 2016
Jul. 31, 2015
Mar. 31, 2013
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]                    
Revenue from transfer of intellectual property and other       $ 18,579,000 $ 18,616,000          
Deferred revenue       145,100,000   $ 145,100,000 $ 145,100,000 $ 162,400,000    
VFMCRP                    
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]                    
Milestone revenue recognized           0        
VFMCRP | Development and License Agreement                    
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]                    
License revenue, initial payment $ 50,000,000     50,000,000            
Royalty revenue, obligation period after first product sale 10 years                  
VFMCRP | Regulatory Milestones                    
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]                    
Additional milestone payment to be received $ 37,000,000                  
VFMCRP | Launch and Sales-based Milestones                    
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]                    
Additional milestone payment to be received 195,000,000                  
VFMCRP | Exclusive Option                    
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]                    
Additional milestone payment to be received $ 555,000,000                  
Pfizer | Collaborative Arrangement, Product                    
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]                    
Additional milestone payment to be received   $ 275,000,000.0                
Non-refundable and non-creditable upfront payment   295,000,000                
Revenue from transfer of intellectual property and other       17,700,000 17,700,000          
Deferred revenue       141,200,000   141,200,000 141,200,000      
Tesaro                    
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]                    
Additional milestone payment to be received     $ 30,000,000              
Milestone revenue recognized       0 $ 0          
Upfront payment under license agreements     6,000,000.0              
Milestone payment received             20,000,000      
Additional milestone payment     $ 85,000,000              
Period from first commercial sale     12 years              
Accrued Expenses | Pfizer | Collaborative Arrangement, Product                    
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]                    
Deferred revenue       70,600,000   70,600,000 70,600,000      
Other Noncurrent Liabilities | Pfizer | Collaborative Arrangement, Product                    
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]                    
Deferred revenue       $ 70,600,000   $ 70,600,000 $ 70,600,000      
Minimum | Pfizer | Collaborative Arrangement, Product                    
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]                    
Each milestone payment   20,000,000                
Maximum | Pfizer | Collaborative Arrangement, Product                    
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]                    
Each milestone payment   $ 90,000,000                
Pharmsynthez                    
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]                    
Ownership percentage       9.00%   9.00% 9.00%      
Rxi Pharmaceuticals Corporation                    
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]                    
Maximum milestone payments to be received                   $ 50,000,000.0
Pharmsynthez Note Receivable | Notes | Pharmsynthez                    
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]                    
Debt face amount                 $ 3,000,000.0